← All trials
NCT04830969
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 8, 2016
- Primary completion
- Jan 28, 2021
- Completion date
- Jan 28, 2021
- First posted
- Apr 5, 2021
- Last posted
- Apr 19, 2021
- Enrollment
- 104
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- State University of New York, BuffaloLead sponsor
- State University of New York, BuffaloReponsible party - principal investigator
- SunstarCollaborator
- State University of New York, BuffaloOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.